Study of Heart and Kidney Protection With Empagliflozin

Dec 23, 2024   |   Dharam J. Kumbhani, MD, SM, FACC

The goal of the EMPA-KIDNEY trial was to assess the safety and efficacy of empagliflozin in improving cardiac and renal outcomes among patients with chronic kidney disease (CKD).

Effectiveness of Intravenous Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency

Nov 08, 2024   |   Dharam J. Kumbhani, MD, SM, FACC

The goal of the IRONMAN trial was to evaluate the safety and efficacy of ferric derisomaltose on cardiovascular outcomes among patients with heart failure (HF) and iron deficiency.

Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid

Jun 26, 2024   |   Anthony A. Bavry, MD,MPH,FACC

The goal of the RESPECT-EPA trial was to evaluate icosapent ethyl, a purified eicosapentaenoic acid (EPA), compared with control among patients with chronic coronary artery disease treated with statin therapy.

Cryoablation to Delay Progression of Persistent Atrial Fibrillation (EARLY-AF Study)

May 01, 2024   |   Fengwei Zou; Luigi Di Biase, MD, PhD, FACC

Atrial fibrillation (AF) is a progressive disease that often starts with predominately sinus rhythm interrupted by paroxysms of AF. As the left atrium becomes more diseased, it progresses into persistent AF and achieving rhythm and rate control...

Lessons Learned From the BEST-CLI and BASIL-2 Trials

Mar 26, 2024   |   Batool Jamal Abuhalimeh, MBBS, FACC; Abdelrhman Abumoawad, MD; Leili Behrooz, MD, MPH; Yulanka Castro Dominguez, MD, FACC; Carlos Mena Hurtado, MD, FACC; Christopher Jennings Regan, MD, FACC

The BEST-CLI (Best Endovascular Versus Best Surgical Therapy in Patients With CLTI) and BASIL-2 (Bypass versus Angioplasty for Severe Ischemia of the Leg-2) trial results provide insight into revascularization strategies among patients with...

Made of Iron: A Look Into the IRONMAN Trial and Iron Deficiency in Patients With HF

Jun 14, 2023   |   Megan Pelter, MD, FACC; Kazuhiko Kido, PharmD, BCCP, BCPS, PhD

Iron deficiency has been proven to be common in patients with heart failure (HF) and is an independent predictor of impaired quality of life and exercise capacity.

Torsemide Comparison With Furosemide for Management of Heart Failure

Jun 13, 2023   |   Anthony A. Bavry, MD,MPH,FACC

The goal of the TRANSFORM-HF trial was to evaluate furosemide compared with torsemide after hospitalization for decompensated heart failure.

ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report

Apr 04, 2023   |   Alison Bailey, MD, FACC; William E. Boden, MD, FACC; Purvi Parwani, MD, FACC; Judith S. Hochman, MD, FACC

In this interview, Judith S. Hochman MD, FACC, FAHA, William E. Boden MD, FACC, FAHA, and Purvi Parwani MBBS, MPH, FACC, discuss ISCHEMIA-EXTENDed – the Follow-Up Interim Report.

Efficacy of the Selective Aldosterone Synthase Inhibitor Baxdrostat for the Treatment of Resistant Hypertension

Apr 03, 2023   |   Leili Behrooz, MD, MPH; Christopher Jennings Regan, MD, FACC

Hypertension is the leading modifiable risk factor for cardiovascular disease worldwide. Resistant hypertension refers to elevated blood pressure (BP) that does not respond adequately to at least three antihypertensive medications of different...

Blood Pressure and Oxygenation Targets in Post Resuscitation Care

Mar 10, 2023   |   Anthony A. Bavry, MD,MPH,FACC

The goal of the BOX trial was to evaluate targeted temperature management for 12 hours after the initial 24-hour targeted temperature period compared with 48 hours among patients who remained comatose after out-of-hospital cardiac arrest.